Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients with Chronic Obstructive Pulmonary Disease Receiving Pravastatin
Resource
AMERICAN JOURNAL OF CARDIOLOGY v.101 n.4 pp.530-535
Journal
The American Journal of Cardiology
Pages
530-535
Date Issued
2008
Date
2008
Author(s)
LEE, TSUNG-MING
LIN, MEI-SHU
CHANG, NEN -CHUNG
Abstract
Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high- sensitivity C- reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double- blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months . Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 +/- 323 seconds at baseline to 922 +/- 328 seconds at the end (p <0.0001) in pravastatin- treated patients. A decrease in hs-CRP over baseline values was observed in 79% of patients (42 of 53) treated with pravastatin. Pravastatin- treated patients with a greater percent decrease in hs-CRP had a significant improvement in exercise time compared with those without hs- CRP decrease. A significant correlation was found in univariate analysis between decrease of log-transformed hs-CRP and increase of exercise time. Baseline hs-CRP and change of hs-CRP were significantly correlated with exercise time, even after adjustment for lipid profiles and hemodynamics. In conclusion, these data reinforce hs-CRP as a significant surrogate marker in COPD and underscore an important guide to the efficacy of treatment in COPD trials.
SDGs
Other Subjects
C reactive protein; cholesterol; hemoglobin; high density lipoprotein cholesterol; interleukin 6; low density lipoprotein cholesterol; placebo; pravastatin; triacylglycerol; adult; aged; article; blood pressure; cholesterol blood level; chronic obstructive lung disease; clinical trial; comparative study; controlled clinical trial; controlled study; correlation analysis; disease marker; drug effect; drug efficacy; dyspnea; exercise; female; follow up; heart rate; hemodynamics; hemoglobin blood level; human; lipid blood level; major clinical study; male; patient compliance; priority journal; protein blood level; randomization; randomized controlled trial; ST segment depression; statistical significance; thorax pain; treatment duration; treatment outcome; triacylglycerol blood level; univariate analysis; unspecified side effect; Aged; Biological Markers; C-Reactive Protein; Cholesterol; Double-Blind Method; Dyspnea; Exercise Test; Exercise Tolerance; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Pravastatin; Pulmonary Disease, Chronic Obstructive
Type
journal article